Stomach Cancer

CLDN18.2 CAR-T Therapy Achieves 48-Month Disease Control and Conversion Surgery in Advanced Gastric Cancer With Peritoneal Metastasis

05/08/2026

A remarkable case published in Journal of Hematology & Oncology highlights the potential of satricabtagene autoleucel (CT041), the world’s first approved solid tumor CAR-T therapy, in treating advanced gastric cancer with peritoneal metastasis. After receiving CT041 following first-line therapy, a 53-year-old patient achieved complete disappearance of peritoneal lesions, underwent successful conversion surgery, and maintained disease control for 48 months.

Satri-cel CAR-T Therapy Shows Long-Term Survival Benefits in Advanced Gastric Cancer with Peritoneal Metastasis

03/08/2026

A phase I clinical study published in Journal of Hematology & Oncology reported long-term outcomes of three advanced gastric cancer patients with peritoneal metastasis treated with Satri-cel (Shuricabtagene Autoleucel). Patients achieved durable peritoneal disease control, with the longest follow-up reaching 48 months.

Why people travel abroad to China for stomach cancer treatment

25/07/2026

China has become a leading destination for stomach cancer treatment, offering innovative therapies, experienced specialists, and access to new treatment options that may not yet be widely available elsewhere.

ASCO 2026: Satri-cel Delivers 4.5+ Years of Benefit

Satri-cel demonstrates durable long-term benefit in advanced gastric cancer: ASCO 2026 update

08/07/2026

At ASCO 2026, CARsgen Therapeutics presented more than 4.5 years of follow-up data demonstrating durable responses, prolonged progression-free survival, and a favorable safety profile for Satri-cel (CT041) in advanced gastric and gastroesophageal junction cancer.

Satri-cel (CT041, Kaileimei) Receives NMPA Approval: The World’s First CAR-T Cell Therapy for Solid Tumors

22/06/2026

Satri-cel injection (CT041, Kaileimei®), the world’s first CAR-T cell therapy for solid tumors, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive, HER2-negative advanced

Gastric Cancer: 66.7% Tumor Reduction and Durable 60-Week Complete Remission

08/05/2026

A novel nanobody-based CAR-T therapy targeting Claudin18.2 has demonstrated remarkable efficacy and safety in gastric and gastroesophageal junction cancers, achieving a 66.7% response rate and sustained complete remission beyond 60 weeks in early clinical trials.

First Solid Tumor CAR-T Therapy Enters CSCO Gastric Cancer Guidelines (2026): A Defining Moment for Clinical Practice

30/04/2026

The inclusion of satri-cel in CSCO guidelines signals a major transition of CAR-T therapy from trials to clinical practice in solid tumors.

2026 China CAR-T Breakthroughs: Revolutionary Progress in Gastric Cancer and Solid Tumors

25/04/2026

China’s CAR-T research has entered a new era in 2026, with major breakthroughs in solid tumors such as gastric cancer, lung cancer, liver cancer, and colorectal cancer. Satri-cel, the world’s leading CLDN18.2-targeted CAR-T therapy, may become the first approved CAR-T treatment for solid tumors globally.

What Is a Solid Tumor? New Treatment Options and the Rise of CAR-T Therapy for Solid Tumors in China

21/04/2026

Solid tumors account for the majority of cancer cases worldwide and remain one of the greatest challenges in modern medicine. While significant advances have been made in surgery, chemotherapy, targeted

The Lancet: Chinese CAR-T Trial Extends Cancer Patients’ Survival by 40%

04/06/2025

A Chinese-led trial has shown CAR-T therapy extends survival in gastric cancer patients by 40%, the first randomized evidence of benefit in solid tumors. Published in The Lancet and presented at ASCO 2025, experts call it a breakthrough in cancer treatment.